and heterogeneity of cases, highlighting the need for a collaborative international approach. In March 2012, the International Encephalitis Consortium held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. This consortium is an ad-hoc committee begun in 2010 with members from the Americas, Europe, Australia, Africa, and Asia. The mission of the consortium is to advance knowledge of the causes, diagnostic strategies, treatment, and outcome of encephalitis, and to implement interventions based upon this knowledge. Topics discussed at the meeting included: (1) standardization of a case definition for encephalitis, (2) development of practical diagnostic algorithms for evaluation of patients, (3) the role of host genetics in encephalitis, and (4) priorities for the study of selected emerging infectious diseases. Here we present a consensus document that synthesizes our discussions and recent literature, with the goals of aiding clinicians evaluating patients with suspected encephalitis and of identifying priorities and approaches to advance knowledge of encephalitis.
PRIORITY 1: CASE DEFINITION
Encephalitis is defined as inflammation of the brain parenchyma associated with neurologic dysfunction [1] . Although pathologic examination and testing of brain tissue is considered to be the "gold standard" diagnostic test for this syndrome, this is rarely done premortem due to potential morbidity associated with an invasive neurosurgical procedure. In the absence of pathologic confirmation, encephalitis has previously been defined on the basis of selected clinical, laboratory, electroencephalographic, and neuroimaging features [2] [3] [4] [5] [6] [7] (Supplementary Table 1 ). One of the most widely used case definitions for encephalitis, developed by the Brighton Collaboration Encephalitis Working Group [6] , standardizes reporting of post-immunization neurologic events. However, whether this definition is applicable to the diagnosis of infectious or autoimmune encephalitis, as well as the relative sensitivity and specificity of the varying levels of diagnostic accuracy of this definition, is unknown.
Further complicating development of a cohesive case definition for encephalitis is the clinical overlap between encephalitis and encephalopathy, terms often used interchangeably in the literature but that may represent distinctive pathophysiologic processes. Encephalopathy refers to a clinical state of altered mental status, manifesting as confusion, disorientation, behavioral changes, or other cognitive impairments, with or without inflammation of brain tissue. Encephalopathy without inflammation can be triggered by a number of metabolic or toxic conditions but may also be associated with specific infectious agents, such as Bartonella henselae [8] [9] [10] or influenza virus [11] [12] [13] [14] .
In contrast, encephalitis is characterized by brain inflammation as a consequence of direct infection of the brain parenchyma, a post-infectious process such as acute disseminated encephalomyelitis (ADEM) [6, 15] , or a noninfectious condition such as anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis [16, 17] . In the absence of pathologic evidence of brain inflammation, an inflammatory response in the cerebrospinal fluid (CSF) or the presence of parenchymal abnormalities on neuroimaging are often used as surrogate markers of brain inflammation. However, encephalitis can occur without significant CSF pleocytosis or demonstrable neuroimaging abnormalities [18] [19] [20] [21] .
Development of a standardized case definition for encephalitis and encephalopathy of presumed infectious etiology is important for epidemiological surveillance, clinical research, and outbreak investigations. Implementation of a case definition broadly applicable to regions with substantially different resources and surveillance capacities facilitates investigation of newly recognized or emerging causes of encephalitis. Because of the significant clinical overlap between encephalitis (infectious and noninfectious) and encephalopathy of presumed infectious etiology, the case definition is formulated to capture both syndromes.
Several caveats must be recognized regarding the proposed case definition. First, alteration in mental status is a required component (Major criterion; Table 1 ). It is recognized that some infections or conditions related to infections may cause central nervous system (CNS) dysfunction without affecting consciousness (eg, post-varicella cerebellar ataxia [22] ), and our case definition would not capture these entities. Second, there is no restriction on the maximum duration of altered mental status, and therefore both acute causes of encephalitis as well as more subacute or chronic infectious conditions such as those caused by fungi or mycobacteria would meet the case definition. Third, several additional criteria are required to substantiate a diagnosis of encephalitis (Minor criteria; Table 1 ). Finally, the syndromic definition is viewed to be complementary to the diagnostic testing algorithm (see Priority 2: Diagnostic Algorithm section and Tables 2 and 3) . Thus, while identification of an infection with an organism that is strongly associated with encephalitis from an appropriate biologic sample would confirm a clinical diagnosis of encephalitis, failure to identify a pathogen, as has been reported in >50% of cases of presumed encephalitis in some series [1, 5] , would not exclude the diagnosis.
Summary
The proposed definition of encephalitis and encephalopathy of presumed infectious etiology was developed based on consensus expert opinion and review of available literature. We anticipate that validation using existing cohorts as well as additional prospective studies will be crucial in refining and improving the case definition for encephalitis.
PRIORITY 2: DIAGNOSTIC ALGORITHM

Scope and Purpose
Algorithms for the diagnosis of encephalitis may serve many purposes, including aiding clinicians in management of patients, standardizing evaluations for research, and facilitating public health disease surveillance. Several groups have recently provided reviews of diagnosis and management of encephalitis, with differing purposes and depth [1, [23] [24] [25] [26] . Our primary goal was to develop a practical diagnostic algorithm for use by medical professionals worldwide in the initial evaluation of suspected encephalitis. In addition, we intended the algorithm to provide a standardized approach for use in collaborative, multicenter research studies. Etiologies that we focus on include those that (1) are more commonly identified, (2) may benefit from targeted therapies, or (3) are of particular public health significance. The algorithm is directed toward identification of specific infectious and autoimmune causes of encephalitis and therefore does not include a broad evaluation for mimickers of encephalitis or other causes of encephalopathy. . MRI may aid in defining an etiology, as localization of inflammation may be suggestive of particular pathogens (eg, temporal lobe involvement in patients with herpes simplex virus encephalitis) or of an autoimmune phenomenon (eg, demyelination in patients with acute disseminated encephalomyelitis). A noncontrast CT scan is most useful in evaluating safety in the performance of a lumbar puncture and in excluding alternative diagnoses such as subarachnoid hemorrhage. We recognize that MRI or CT may not be available in resource-limited settings, in which case the diagnosis of encephalitis will need to rely on clinical and laboratory criteria. f EEG abnormalities reported in cases of encephalitis range from nonspecific generalized slowing to distinctive patterns suggestive of specific entities, including repetitive sharp wave complexes over the temporal lobes or periodic lateralizing epileptiform discharges in HSV-1 (Lai and Gragasin J Clin Neurophysiol 1988 5:87-103) and bilateral synchronous periodic sharp and slow waves associated with subacute sclerosing panencephalitis (Gutierrez et al. Dev Med Child Neurol 2010 52:901-7). EEG abnormalities are frequently nonspecific and may be attributable to medications or metabolic abnormalities. The EEG may identify epileptiform discharges in the absence of clinical evidence of seizure activity (subclinical or nonconvulsive status epilepticus) as a cause of obtundation. Relatively few causes account for the vast majority of identified cases of encephalitis [5, 7, 27] . Therefore, we recommend testing for these agents, along with selected, treatable conditions, in all individuals. Obtaining a comprehensive case history, including recent and remote travel, animal contacts and insect exposure, and carefully characterizing presenting symptoms, signs, and laboratory and neuroimaging findings are crucial to inform additional testing (Tables 2 and 3 ). We developed distinct algorithms for adult and pediatric populations, because the spectrum and frequencies of etiologies differ between the 2 age groups [27] . We recommend . Consultation with local health authorities is also recommended. b MTB testing includes CSF smear for acid-fast bacilli and CSF mycobacterial culture along with one or more of the number of MTB PCR tests for CSF now commercially available. Sensitivity of smear and culture increases with the volume of CSF analyzed; we recommend consulting with the laboratory regarding optimal volumes of CSF to be analyzed. Given the varying sensitivity of these tests, systemic MTB testing including tuberculin skin test (may be negative) or interferon gamma release assay, stains and cultures from sputum, and tissue from biopsies from any potential systemic sites of infection. c Fungal testing should be tailored to specific geographic region and prior travel history/place of residence, and typically consists of serology, antibody testing from urine and/or CSF, and cultures from blood and CSF. d Arbovirus testing should be tailored to specific geographic region and typically consists of IgG and IgM from serum and CSF; PCR (serum, CSF) can be performed for select arboviruses (ie, WNV, California serogroup viruses), and is particularly useful in immunocompromised patients. e Rabies/ABLV testing includes serologic analysis of serum and CSF; virus isolation or RT-PCR from saliva; tests for viral antigen or histopathology on either a brain biopsy or full-thickness biopsy of the nape of the neck. Testing should be conducted in concert with a local or regional public health department. f Tick borne disease testing should be tailored to specific geographic region and typically consists of serology (ie, Borrelia, Ehrlichia, Rickettsia sp., Anaplasma phagocytophilum, TBEV), and blood PCR (Ehrlichia, Anaplasma). g Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba spp. testing is only available at specialized laboratories (eg, CDC) and includes serum immunofluorescence assay, immunohistochemistry on brain or other tissue and PCR testing on brain or other tissue and CSF. In addition, CSF wet mount is recommended for Naeglaeria fowleri testing. Brain tissue from affected region offers optimal sensitivity and specificity but other specimens can be tested. h Autoimmune limbic encephalitis evaluation includes testing for antibodies to VGKC (most commonly identified cause in adults), GAD, AMPA receptor, GABA b receptor, mgluR5, Hu, CV2, Ma2, and amphiphysin. i Respiratory virus testing includes either culture or respiratory PCR panel from respiratory specimens (eg, nasopharyngeal swab, nasal wash). Respiratory virus testing should include Influenza A and B (during influenza season). Testing for other respiratory viruses such as parainfluenza and adenovirus should be considered although their role in causing CNS illness is controversial. j Limited testing may be available through research laboratories, and includes examination of CSF or other affected tissues (ie, eye, muscle) for presence of parasite, or detection of antibody in serum or CSF. . Consultation with local health authorities is also recommended. b Although some members of the consortium recommended M. pneumoniae CSF PCR as routine testing for all children, a consensus was not reached given the challenges of establishing a diagnosis of encephalitis due to M. pneumoniae (see text). c MTB testing includes CSF smear for acid-fast bacilli and CSF mycobacterial culture along with one or more of the number of MTB PCR tests for CSF now commercially available. Sensitivity of smear and culture increases with the volume of CSF analyzed; we recommend consulting with the laboratory regarding optimal volumes of CSF to be analyzed. Given the varying sensitivity of these tests, systemic MTB testing including tuberculin skin test (may be negative) or interferon gamma release assay, stains and cultures from sputum, and tissue from biopsies from any potential systemic sites of infection. d Fungal testing should be tailored to specific geographic region and prior travel history/place of residence, and typically consists of serology, antibody testing from urine and/or CSF, and cultures from blood and CSF. e Arbovirus testing should be tailored to specific geographic region and typically consists of IgG and IgM from serum and CSF; PCR (serum, CSF) can be performed for select arboviruses (ie, WNV, California serogroup viruses), and is particularly useful in immunocompromised patients. f Rabies/ABLV testing includes serologic analysis of serum and CSF; virus isolation or RT-PCR from saliva; tests for viral antigen or histopathology on either a brain biopsy or full-thickness biopsy of the nape of the neck. Testing should be conducted in concert with a local or regional public health department. g Tick borne disease testing should be tailored to specific geographic region and typically consists of serology (ie, Borrelia, Ehrlichia, Rickettsia sp., Anaplasma phagocytophilum, TBEV), and blood PCR (Ehrlichia, Anaplasma). h Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba spp. testing is only available at specialized laboratories (eg, CDC) and includes serum immunofluorescence assay, immunohistochemistry on brain or other tissue and PCR testing on brain or other tissue and CSF. In addition, CSF wet mount is recommended for Naeglaeria fowleri testing. Brain tissue from affected region offers optimal sensitivity and specificity but other specimens can be tested. i Respiratory virus testing includes either culture or respiratory PCR panel from respiratory specimens (eg, nasopharyngeal swab, nasal wash). Respiratory virus testing should include Influenza A and B (during influenza season). Testing for other respiratory viruses including Parainfluenza 1-4, Adenovirus, and human metapneumovirus should be considered although their role in causing CNS illness is controversial. j Autoimmune limbic encephalitis evaluation includes testing for antibodies to VGKC, GAD, AMPA receptor, GABA b receptor, mgluR5, Hu, CV2, Ma2, and amphiphysin. k Limited testing may be available through research laboratories, and includes examination of CSF or other affected tissues (ie, eye, muscle) for presence of parasite, or detection of antibody in serum or CSF.
neuroimaging ( preferably magnetic resonance imaging [MRI]), electroencephalography (EEG), and lumbar puncture (LP) in all individuals unless contraindicated [28] , because such testing may confirm the diagnosis of encephalitis and establish the etiology. If the etiology of encephalitis is not rapidly identified or where unique epidemiologic factors or clinical features are present, we recommend referring to several recent publications as a guide to further evaluation [1, [23] [24] [25] [26] . Our recommendations incorporate large-scale geographic considerations; however, specific travel history or geographic information should prompt consultation with regional public health departments. Because our focus is on initial evaluation of patients, modalities such as brain biopsy, typically reserved for refractory cases of encephalitis, are not included. Moreover, our knowledge of autoimmune encephalitis is rapidly changing, with ongoing identification of novel autoantibodies and expansion of clinical spectra of disease. Here, we include well-recognized syndromes and relatively common etiologies [29, 30] . Overall, it should be noted that our recommendations provide general guidance for initial evaluation of encephalitis, but rapid advances in autoimmune encephalitis coupled with the emerging nature of infections warrant ongoing evaluation of testing paradigms.
Selected Etiology-specific Considerations
Herpes Simplex Virus (HSV) Case series and studies have shown that HSV polymerase chain reaction (PCR) can be falsely negative, especially among children and early in the disease course [18, 21, 31] . If testing from the first LP is negative and herpes simplex encephalitis (HSE) is still of concern (eg, temporal lobe involvement seen on neuroimaging), a second LP should be repeated within 3-7 days with CSF sent for HSV PCR [1] . Testing for intrathecal HSV antibodies may complement molecular testing but is not typically useful for acute patient management [32] .
Varicella-zoster Virus (VZV)
VZV is one of the most commonly identified causes of acute encephalitis in adults [5, 7] , typically associated with viral reactivation and resulting in a CNS vasculopathy [33] . Notably, CNS reactivation may occur in the absence of skin lesions [34] . In children, on the other hand, most cases occur concurrently with chickenpox or in a post-infectious form [22, 35] . Detection of antibodies to VZV in the CSF appears to have greater sensitivity than detection of viral DNA [36] ; therefore, we recommend that both assays be sent when possible.
Enteroviruses (EV)
CSF PCR analysis is crucial to perform but alone may be insufficient for diagnosis. In one report of an EV71 outbreak, EV-PCR of CSF yielded positive results in only 31% of cases, with higher yields from PCR of throat and stool specimens [37] . Because enteroviral shedding from the gastrointestinal tract may persist for weeks following infection [38] , we recommend testing of both CNS and extra-CNS samples. Moreover, because standard EV PCR assays do not detect parechoviruses, specific PCR assays for these viruses should be performed in young children.
Epstein-Barr Virus (EBV)
EBV is an important cause of encephalitis in the pediatric population, particularly among adolescents. Although helpful in diagnosis of EBV-associated encephalitis, PCR testing can be associated with false-negative and false-positive results, the latter often occurring due to presence of EBV DNA in peripheral blood mononuclear cells. Therefore, serology, including antiviral capsid antigens (VCA) immunoglobulin M/immunoglobulin G (IgM/IgG) and anti-Epstein-Barr nuclear antigen (EBNA), is recommended in addition to CSF PCR [39] .
Human Herpesvirus 6 (HHV-6)
The CNS pathogenic potential of HHV-6 has yet to be defined, although increasing evidence implicates its role in limbic encephalitis in the immunocompromised individual [40] . A positive HHV-6 CSF PCR should prompt corresponding evaluation of blood PCR levels in an effort to distinguish between chromosomal integration and acute infection [41] . Notably, latent disease can also be detected through PCR and may be a confounder [42] .
Arboviruses
For most arboviruses, serologic testing of serum and CSF is preferred to molecular testing, since the peak of viremia typically occurs prior to symptom onset. For example, in patients with West Nile virus (WNV) associated with neuroinvasive disease, CSF PCR is relatively insensitive (57%) compared with detection of WNV IgM in CSF [43] . The cumulative percentage of seropositive patients increases by approximately 10% per day during the first week of illness, suggesting the need for repeat testing if the suspicion for disease is strong in those with initially negative results [44, 45] . Notably, arbovirus IgM antibodies may be persistently detectable in the serum and, less commonly, in the CSF, for many months after acute infection, and therefore may not be indicative of a current infection [46, 47] . Therefore, if possible, documentation of acute infection by seroconversion and/or 4-fold or greater rises in titre using paired sera is recommended.
Mycoplasma pneumoniae
Several reports have implicated Mycoplasma pneumoniae as a leading cause of encephalitis, particularly among children [48, 49] . In most such cases an immune-mediated mechanism is hypothesized; a preceding respiratory prodrome and detection of the pathogen in the respiratory tract, but not CSF, is typical of such cases. Direct infection of the brain or CSF is less common but has been observed in both adults and children. Serology alone is unreliable in diagnosing neurologic disease due to M. pneumoniae because of the high background incidence of acute infections and limited specificity of currently available assays [50] . Similarly, because detection of M. pneumoniae DNA in respiratory secretions may reflect acute infection, remote infection or asymptomatic colonization its detection does not establish it as the cause of neurologic disease. We recommend that testing be performed in pediatric patients and include both serology and PCR analysis. Overall, the strength of microbiologic evidence needs to be considered when implicating M. pneumoniae as the cause of encephalitis [51] .
Anti-NMDA Receptor (NMDAR) Encephalitis
Affected individuals typically develop prominent psychiatric symptoms, cognitive dysfunction, seizures, orofacial dyskinesias, and autonomic instability [52, 53] . Sensitivity of testing is approximately 15% higher from the CSF than from serum, as determined by comparison of paired serum and CSF samples [54] . Notably, the recent demonstration of serum or CSF antibodies to NMDAR in 30% of individuals during the course of typical HSE suggests that a positive antibody result should be interpreted in the proper clinical context [55] .
Autoimmune Limbic Encephalitis (ALE) ALE, characterized by rapidly progressive short-term memory deficits, psychiatric symptoms, and seizures, is associated with a wide variety of autoantibodies, including onconeuronal antibodies (ie, Hu, CV2, Ma2, amphiphysin) and antibodies to neuronal cell surface/ synaptic antigens (ie, voltage gated potassium channel [VGKC], glutamic acid decarboxylase, AMPA receptor, GABA b receptor, mgluR5). Although the former group is highly associated with underlying tumor, in the latter group the presence of malignancy is variable. In most cases, serum testing is sufficient [56] .
Summary
This algorithm represents a practical tool for use by clinicians in initial evaluation of patients with suspected encephalitis and provides the basis for worldwide collaboration to advance diagnosis and management of affected individuals. To maximize the benefits of such an approach for research purposes, the use of standardized case history forms with relevant demographic and laboratory data is critical.
PRIORITY 3: HOST GENETICS
Introduction
Although encephalitis is typically a rare clinical entity, it follows infection with a number of relatively common agents. Reasons for this range of disease severity remain unclear. Several general and disease-specific risk modifiers have been identified, including infectious dose, viral or microbial genotypic variation, and age-related changes in anatomic barriers or global immune function. In addition, an individual's genetic make-up contributes significantly to the variation in infectious disease susceptibility and severity [57] . Preclinical studies have identified host cell factors that modulate the course of infection for a range of microbes. With few exceptions, however, these studies have failed to identify genes in which human variation affects disease outcome. Indeed, risk alleles for infectious encephalitis have only been identified in a handful of cases (Table 4 and references).
Challenges and Solutions
The rarity and highly sporadic nature of encephalitis presents certain challenges. The strategy and approach to identifying genotypic determinants of a given phenotype depends largely on its allelic architecture-the number, type, penetrance, and frequency of disease associated variants (Supplementary Table 2 ) [58] . Mendelian traits, representing one extreme on the allelic spectrum, are determined by variants at a single locus. Because Mendelian variants are associated with a high relative risk of disease, they tend to be very rare in populations. Such traits have typically been dissected through linkage studies of families. While this approach has successfully identified genes involved in primary immunodeficiency, it is difficult to identify large pedigrees with multiple exposed and affected individuals for encephalitis and many other infectious diseases [57] . Genomewide resequencing of unrelated cases has emerged as another promising approach in Mendelian disease genetics. This strategy can identify candidate genes with as few as 10-50 individuals, but the case only design necessitates larger validation studies with appropriate controls [59, 60] .
On the other end of the allelic spectrum are common genetic variants, which typically have only a modest effect on a disease phenotype. The common disease-common variant hypothesis predicts that many prevalent diseases are the result of common variants in multiple genetic loci, each with a small relative risk. These loci are typically identified in case-control association studies, although even the best candidate gene studies are prone to confounding and bias. While genomewide association studies circumvent many of these issues, adequate statistical power requires recruitment of hundreds or thousands of affected cases and exposed controls [61] . Even then, current study designs are poorly sensitive for rare alleles.
Given the large number of cases required and the cost of genomewide studies, human genetics has become a highly collaborative enterprise. However, many challenges exist in organizing such a genetics research effort. Above all, a multicenter approach will require a set of standard protocols for prospective subject recruitment, informed consent, biospecimen collection, and storage. While many investigators routinely collect serum and CSF from enrolled patients, protocols would need to be expanded to include snap-frozen whole blood with explicit authorization for future use in genetic studies. Similarly, common case history forms are needed to record demographics and relevant risk factors. Ideally, the biospecimens and clinical metadata would be curated and maintained in a central biobank with a mature informational technology infrastructure. The cost of such efforts would be significant. The group also discussed how research efforts could impact the diagnosis and management of encephalitis. The rapid pace of gene discovery suggests a future in which genetic testing targets high-risk patients in need of immunization or those who would benefit from specific therapeutic interventions. This approach is now commonplace in oncology. In infectious disease, testing for HLA-B5701 is used to identify patients infected with human immunodeficiency virus (HIV) at risk for abacavir hypersensitivity [62] , and IL-28B genotype may predict the clinical efficacy of interferon regimens for hepatitis C [63] .
Summary
Overall, the identification of genetic risk factors for encephalitis and other neuroinvasive complications of infection is a priority research area. We expect that a more complete understanding of encephalitis host genetics will elucidate pathogenic mechanisms, define relevant biomarkers, and suggest potential therapeutic approaches. As is the case for clinical risk factors, genetic risk factors for encephalitis will likely include alleles that are pathogen-specific as well as mutations that confer broad susceptibility to encephalitis [64] . More work is clearly needed in this area, and this and other consortia can play a productive role in this movement to personalized medicine.
PRIORITY 4: SELECTED EMERGING AREAS
A discussion of selected emerging areas in encephalitis was held together with colleagues from the Centers for Disease Control and Prevention and Public Health Agency of Canada who attended our consortium meeting. Here, we identify priorities for the study of three pathogen groups: arboviruses, lyssaviruses (including rabies), and free living amoebae (FLA) ( Table 5) .
Arboviruses
Most arboviruses of medical importance belong to 3 families: Flaviviridae, Togaviridae, and Bunyaviridae [65, 66] . Japanese encephalitis virus ( JEV) is the leading cause of mosquito-borne encephalitis globally and continues to expand its range, Tickborne encephalitis virus (TBEV) is the most common arthropod transmitted viral infection of humans in Europe, and increasing numbers of cases of neuroinvasive disease have been documented in North America involving tick-transmitted Powassan virus [66] [67] [68] [69] . West Nile virus (WNV) has re-emerged as an important cause of encephalitis in the United States and Europe, and there has been increasing recognition of dengue (the most common arboviral infection worldwide) and chikungunya viruses as causes of neurological complications [70] [71] [72] [73] [74] . La Crosse virus continues to be a leading cause of pediatric encephalitis in the United States, whereas detection of other members of the California serogroup causing severe disease may be hampered by a lack of commercially available diagnostic assays and low level surveillance [75, 76] (Table 5) .
Lyssaviruses
Rabies, an acute progressive viral encephalitis with the highest case fatality known for any agent, is caused by viruses in the family Rhabdoviridae, genus Lyssavirus. Although rabies is one of the oldest infectious diseases, and efficacious human and animal vaccines were developed decades ago, the global public health and veterinary burden remains high. Tens of thousands of human deaths, and millions of exposures, occur annually, mostly in developing countries [77] . Reservoirs predominate among the Carnivora and Chiroptera (bats) [78, 79] . Outcome after exposure likely represents a continuum, defined in part by viral type, dose, route, and poorly understood host attributes [80, 81] . The reduction of exposure to rabid animals and postexposure prophylaxis after an animal bite are the 2 most relevant strategies to prevent additional human cases [82] [83] [84] . Elimination of canine rabies by mass vaccination, humane population management, and production of more effective, less costly biologics are solutions to reduce the burden [85, 86] (Table 5) .
Free Living Amoebae (FLA)
Several FLA, including Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba spp. cause CNS infections. N. fowleri causes primary amoebic meningoencephalitis (PAM), whereas B. mandrillaris and Acanthamoeba spp. generally cause a more chronic disease, granulomatous amebic encephalitis (GAE). Although case reports of PAM are rare, many additional cases likely go unrecognized, as suggested by the 75% of US PAM cases that are diagnosed postmortem (CDC unpublished data). Prior to 2010, PAM cases were reported only from southern US states. Recently, however, 4 cases were reported from Northern and Midwestern states (CDC unpublished data). Exposure to FLA is believed to be common; a recent serologic investigation showed 3%-4% of individuals with evidence of B. mandrillaris exposure [87] . It remains unclear why some develop disease while the majority of those exposed do not [88] . B. mandrillaris GAE, previously only reported as isolated cases, has recently been diagnosed in multiple organ transplant recipients where the donor was found to have had B. mandrillaris infection, highlighting this organism as a potentially under-recognized cause of fatal encephalitis [89, 90] . Our knowledge of the contribution of FLA to human disease is limited by the lack of consistent surveillance data and a restricted understanding of the ecology of FLA (Table 5) .
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
Notes
